Mereo BioPharma

Mereo BioPharma Group plc (NASDAQ: MREO) is a clinical-stage biopharmaceutical company incorporated in 2015 and headquartered in London, United Kingdom, developing therapeutics for rare diseases. Its portfolio is built around setrusumab, an anti-sclerostin antibody for osteogenesis imperfecta developed with partner Ultragenyx; alvelestat, an oral small molecule for alpha-1 antitrypsin deficiency-associated lung disease, which was the subject of an August 2026 option and license agreement with Sentynl Therapeutics; and vantictumab, an anti-FZD monoclonal antibody for autosomal dominant osteopetrosis type 2, alongside earlier-stage assets acquired from AstraZeneca and other partners. On September 11, 2026, the company's American Depositary Shares rose 14.47% to $0.28 on below-average volume, a low-price bounce rather than a reaction to a new disclosure; the ADSs trade well below Nasdaq's $1.00 minimum bid price and the company holds a compliance window running to February 16, 2027.